Castle Biosciences — Third Quarter 2026 Earnings Summary

Castle Biosciences reported third-quarter 2026 revenue of $102.9 million, representing a 24% increase compared to the same period in 2025, driven by a 47% year-over-year growth in TissueCypher test report volume. The company raised its full-year 2026 revenue guidance to a range of $385 million to $395 million, up from the previous forecast of $365 million to $375 million. For the nine months ended September 30, 2026, the company generated $290.1 million in revenue and reported a net loss of $20.7 million, while maintaining positive Adjusted EBITDA expectations for the remainder of 2026 and the full year 2027.